Search
Semaglutide Clinical Trials
A collection of 179 research studies where Semaglutide is the intervention. These studies are located in the United States. Semaglutide is used for conditions such as Diabetes Mellitus, Type 2, Obesity and Diabetes.
97 - 108 of 179
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
Studying an Investigational Virus Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Healthy
Interested in vaccine studies
All Conditions
Preventative Trials
Latino Semaglutide Study
Completed
The purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss. This study may lead to the development of other related medications for assisting people with the disease of obesity.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/09/2024
Locations: Loma Linda University Health, Loma Linda, California
Conditions: Obesity, Obesity; Drug, Overweight or Obesity, Weight Loss, Weight Loss Trajectory, Weight, Body
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
Completed
This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight.
This study will compare the effect of semaglutide (a new medicine) compared to "dummy" medicine on body weight and heart failure symptoms.
Participants will either get semaglutide or "dummy" medicine, which treatment participants get is decided by chance.
Participants will need to take 1 injection once a week. The study medicine is injec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: Eastern Shore Rsrch Inst, LLC, Fairhope, Alabama +117 locations
Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
Active Not Recruiting
A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 agonist therapy in subjects with overweight or obesity
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/01/2024
Locations: ProSciento CRU, Chula Vista, California +6 locations
Conditions: Overweight and Obesity
Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data
Completed
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a GLP-1 Agonist
Completed
Adult participants with BMI between 22 - 35 kg/m2 will be enrolled and randomized to receive either NG101 (20 mg BID) or placebo for 5 days beginning on Day 1. On Day 2, all participants will receive a single subcutaneous injection of a GLP-1 agonist (semaglutide). Participants will remain at the clinical research unit for the duration of the treatment period.
The goal of this clinical trial is to evaluate the safety and efficacy of NG101 compared to placebo, when also administered along with a... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
09/23/2024
Locations: Celerion, Tempe, Arizona
Conditions: Overweight and Obesity, Healthy
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
Completed
The study compares two semaglutide medicines and looks at how well they control blood sugar levels, in participants with type 2 diabetes (T2D). Participants will either get the currently available semaglutide or the semaglutide which is produced through a new manufacturing process. Participants need to take one injection of semaglutide once a week, on the same day of every week. Participants will have a total of 11 clinic visits and the study will last for about 35 weeks (approximately 8 months)... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
09/16/2024
Locations: Velocity Clinical Research San Diego, La Mesa, California +64 locations
Conditions: Diabetes Mellitus, Type 2
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
Completed
The purpose of this study was to evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in people living with HIV (PLWH), central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2024
Locations: Alabama CRS (Site ID: 31788), Birmingham, Alabama +8 locations
Conditions: HIV Infections, Non-Alcoholic Fatty Liver Disease
A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People
Completed
The aim of this study is to investigate the amount of the active ingredient and helping agent in the blood in two different tablet versions of Semaglutide. The study will consist of 3 groups and the treatment the participants will get is dependent on the group the participants will be enrolled in.
The participants in group 1 will receive treatment for 22 weeks, group 2 for 21 weeks and group 3 for 20 weeks.
The study will last up to 29 to 31 weeks for each participant. This includes a screenin... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
09/06/2024
Locations: Altasciences Clinical LA, Inc., Cypress, California +2 locations
Conditions: Healthy Volunteers, Type 2 Diabetes
A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants
Completed
In this study, a known investigational medicine called 'semaglutide' will be tested in 2 different tablet versions. In addition to semaglutide, the tablet versions contain different helping agents in different amounts. Both tablet versions have a helping agent called SNAC. The main aim of this study is to investigate semaglutide of 4 different doses in a new tablet by determining the amount of semaglutide in the blood and compare the concentration in the blood for the new tablet with the tablet... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
09/06/2024
Locations: Altasciences Clinical LA, Inc., Cypress, California +1 locations
Conditions: Healthy Participants
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
Completed
The study is looking at a new medicine to help people lose weight. In this study participants will either get semaglutide and NNC0165-1875 or semaglutide and a "dummy" medicine (placebo). Which treatment participants get is decided by chance. Participants will get 2 injections per week, on the same day. Participants will have to take the study medicine by use of a pre-filled pen. A pen is a medical tool with a needle used for injections under the skin. The study doctor or staff will show partici... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/05/2024
Locations: Diablo Clinical Research, Inc., Walnut Creek, California +13 locations
Conditions: Obesity
Semaglutide Use in Elderly Obese Patients
Active Not Recruiting
This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly obese subjects on body weight and body composition as assessed by DEXA.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
08/27/2024
Locations: Diabetes and Endocrinology Research Center, Buffalo, New York
Conditions: Obesity, Aging
Effects of Semaglutide on Nicotine Intake
Completed
Tobacco use remains the foremost cause of preventable deaths in the U.S. and worldwide. Advancing new smoking cessation therapies, including those targeting novel biological mechanisms, is a critical public health priority. Accumulating evidence from preclinical studies suggests that glucagon-like peptide-1 (GLP-1) receptor agonists reduce intake and/or reinstatement of addictive drugs, including nicotine. However, translational work is necessary to establish whether GLP-1 receptor agonists alte... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
08/12/2024
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Tobacco Use Disorder, Nicotine Addiction
97 - 108 of 179